FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2960511059> ?p ?o ?g. }

• W2960511059 endingPage "1244" @default.
• W2960511059 startingPage "1239" @default.
• W2960511059 abstract "Purpose: To investigate the efficacy and safety of interferon (IFN) alpha-2b eye drops in preventing pterygium recurrence after the bare sclera technique. Methods: Sixty eyes in 53 patients who underwent treatment for primary pterygium (the length of corneal invasion ranged from 2 to 4 mm) were enrolled in this prospective study. All patients were divided in chronological sequence into 2 groups. The control group included the first 30 eyes, whereas the treatment group included the next 30 eyes. After treatment with the bare sclera technique, levofloxacin and 0.1% fluorometholone eye drops were used 4 times a day for 3 months after surgical excision in both groups. In addition, IFN alpha-2b eye drops were applied in the treatment group 4 times a day for 3 months. Throughout an 18-month follow-up period, all patients in both groups were examined 1 day, 10 days, 1 month, 3 months, 6 months, 12 months, and 18 months after surgery. The main outcome measures were pterygium recurrence, conjunctival redness and thickness, and neovascularization and complications (ie, delayed conjunctival healing, persistent corneal epithelial defection, conjunctival granuloma, and scleral melting and necrosis). Results: The recurrence rates in the control group and the treatment group at the end of the sixth month were 29.2% and 3.7%, respectively, and the rates were significantly different between the 2 groups (P = 0.019). Up to 12 months after surgeries, the recurrence rate was 33.3% in the control group and 7.4% in the treatment group, and the difference between the 2 groups was statistically significant (P = 0.048). The rates at the end of 18 months were the same. During the follow-up period, no complications were observed except for 1 conjunctival granuloma (in the treatment group) and 2 corneal epithelial defects (one in the control group and the other in the treatment group). Conclusions: Administration of IFN alpha-2b eye drops after the bare sclera technique appear safe and effective in reducing the recurrence of pterygium." @default.
• W2960511059 created "2019-07-23" @default.
• W2960511059 creator A5003354149 @default.
• W2960511059 creator A5028956216 @default.
• W2960511059 creator A5039095985 @default.
• W2960511059 creator A5039487627 @default.
• W2960511059 creator A5059234887 @default.
• W2960511059 creator A5074480404 @default.
• W2960511059 date "2019-07-03" @default.
• W2960511059 modified "2023-09-23" @default.
• W2960511059 title "Interferon Alpha-2b Eye Drops Prevent Recurrence of Pterygium After the Bare Sclera Technique: A Single-Center, Sequential, and Controlled Study" @default.
• W2960511059 cites W1129568285 @default.
• W2960511059 cites W1567628127 @default.
• W2960511059 cites W1638465953 @default.
• W2960511059 cites W1694440667 @default.
• W2960511059 cites W1971613885 @default.
• W2960511059 cites W1997819200 @default.
• W2960511059 cites W1998121045 @default.
• W2960511059 cites W2012290478 @default.
• W2960511059 cites W2015737367 @default.
• W2960511059 cites W2023189174 @default.
• W2960511059 cites W2034119344 @default.
• W2960511059 cites W2043651574 @default.
• W2960511059 cites W2048847543 @default.
• W2960511059 cites W2058068089 @default.
• W2960511059 cites W2063585489 @default.
• W2960511059 cites W2070798536 @default.
• W2960511059 cites W2076654028 @default.
• W2960511059 cites W2077575831 @default.
• W2960511059 cites W2086697097 @default.
• W2960511059 cites W2093289540 @default.
• W2960511059 cites W2126350203 @default.
• W2960511059 cites W2135598383 @default.
• W2960511059 cites W2160544156 @default.
• W2960511059 cites W2172405413 @default.
• W2960511059 cites W2186511842 @default.
• W2960511059 cites W2207717195 @default.
• W2960511059 cites W2298989419 @default.
• W2960511059 cites W2300126200 @default.
• W2960511059 cites W2322784573 @default.
• W2960511059 cites W2409056716 @default.
• W2960511059 cites W2438179131 @default.
• W2960511059 cites W2522353500 @default.
• W2960511059 cites W2578050687 @default.
• W2960511059 cites W2578837011 @default.
• W2960511059 cites W2607220272 @default.
• W2960511059 cites W2607427523 @default.
• W2960511059 cites W2765095237 @default.
• W2960511059 cites W71096807 @default.
• W2960511059 doi "https://doi.org/10.1097/ico.0000000000001995" @default.
• W2960511059 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6750146" @default.
• W2960511059 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31913906" @default.
• W2960511059 hasPublicationYear "2019" @default.
• W2960511059 type Work @default.
• W2960511059 sameAs 2960511059 @default.
• W2960511059 citedByCount "12" @default.
• W2960511059 countsByYear W29605110592019 @default.
• W2960511059 countsByYear W29605110592020 @default.
• W2960511059 countsByYear W29605110592021 @default.
• W2960511059 countsByYear W29605110592023 @default.
• W2960511059 crossrefType "journal-article" @default.
• W2960511059 hasAuthorship W2960511059A5003354149 @default.
• W2960511059 hasAuthorship W2960511059A5028956216 @default.
• W2960511059 hasAuthorship W2960511059A5039095985 @default.
• W2960511059 hasAuthorship W2960511059A5039487627 @default.
• W2960511059 hasAuthorship W2960511059A5059234887 @default.
• W2960511059 hasAuthorship W2960511059A5074480404 @default.
• W2960511059 hasBestOaLocation W29605110592 @default.
• W2960511059 hasConcept C118487528 @default.
• W2960511059 hasConcept C141071460 @default.
• W2960511059 hasConcept C142724271 @default.
• W2960511059 hasConcept C2775984611 @default.
• W2960511059 hasConcept C2777100477 @default.
• W2960511059 hasConcept C2778266423 @default.
• W2960511059 hasConcept C2780073493 @default.
• W2960511059 hasConcept C71924100 @default.
• W2960511059 hasConceptScore W2960511059C118487528 @default.
• W2960511059 hasConceptScore W2960511059C141071460 @default.
• W2960511059 hasConceptScore W2960511059C142724271 @default.
• W2960511059 hasConceptScore W2960511059C2775984611 @default.
• W2960511059 hasConceptScore W2960511059C2777100477 @default.
• W2960511059 hasConceptScore W2960511059C2778266423 @default.
• W2960511059 hasConceptScore W2960511059C2780073493 @default.
• W2960511059 hasConceptScore W2960511059C71924100 @default.
• W2960511059 hasIssue "10" @default.
• W2960511059 hasLocation W29605110591 @default.
• W2960511059 hasLocation W29605110592 @default.
• W2960511059 hasLocation W29605110593 @default.
• W2960511059 hasLocation W29605110594 @default.
• W2960511059 hasOpenAccess W2960511059 @default.
• W2960511059 hasPrimaryLocation W29605110591 @default.
• W2960511059 hasRelatedWork W2022790552 @default.
• W2960511059 hasRelatedWork W2155186726 @default.
• W2960511059 hasRelatedWork W2334705407 @default.
• W2960511059 hasRelatedWork W2378620782 @default.
• W2960511059 hasRelatedWork W2388584588 @default.
• W2960511059 hasRelatedWork W2424441330 @default.
• W2960511059 hasRelatedWork W2529702553 @default.

• next